June 4, 2010 โ€“ One-year mortality rates were very low for 1,038 high-risk patients, many of whom were too sick to undergo traditional open-heart surgery, who received the Sapien transcatheter heart valve. Results of the SOURCE Registry were presented last week at EuroPCR in Paris.

June 4, 2010 โ€“ Speech understanding technology that accepts data and translates additional physician dictation in real time into a structured document was introduced yesterday at the Annual Meeting of the Society of Imaging Informatics in Medicine (SIIM) in Minneapolis.

June 4, 2010 โ€“ The first national contract signed for a magnetic resonance imaging angiography (MRA) contrast agent was been signed, making it available to more than 27,000 medical facilities.

June 4, 2010 โ€“ A monthly, online service was launched today that allows clinicians to review and interpret general and cardiac nuclear medicine studies from anywhere in the world for a low monthly rate. The Medx Web Viewer permits interpretation of any original equipment manufacturer (OEM) dataset with nuclear medicine-specific color tables and cine movie displays.

June 3, 2010 โ€“ Six-month data from the first 45 patients enrolled in the second stage of a trial for a bioresorbable stent demonstrated strong results. Abbott's bioresorbable vascular scaffold (BVS) showed a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots.

June 3, 2010 โ€“ A joint research agreement will explore the targeted delivery of experimental therapeutics based on ribonucleic acid (RNA) interference (RNAi). Philips Healthcare and RXi Pharmaceuticals Corp. say imaging compounds based on RNAi represent a promising new class of drugs for the targeted treatment of a number of diseases including cancer and cardiovascular disease.

June 3, 2010 โ€“ A single photon emission tomography (SPECT) system may significantly reduce patient and staff radiation exposure by using significantly less radioactive imaging agent.

June 2, 2010 โ€“ Covidien announced yesterday it is purchasing ev3 Inc. for $2.6 billion to expand its percutaneous vascular portfolio. The company hopes to become a leading endovascular player in both the peripheral vascular and neurovascular markets.

June 2, 2010 โ€“ A portable point-of-care prothrombin time/international normalized ratio (PT/INR) analyzer was released this week. The system detect blood clotting time for patients stabilized on oral anticoagulation medications such as warfarin. The CoaguSense PT/INR monitoring system was recently cleared by the U.S.

June 2, 2010 โ€“ Key research on new diagnostic uses for cardiac ultrasound will be presented at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions June 12-15, in San Diego.

Leading experts in cardiology will present and discuss the latest clinical and research developments in adult and pediatric echocardiography. Among the key presentations are:

Subscribe to
ยฉ Copyright Wainscot Media. All Rights Reserved.
Subscribe Now